# OnCo record nct04513717 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04513717/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04513717", "NCT04513717" ;
  schema:name "Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial"@en ;
  schema:description "A phase 3 trial of Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin / leuprolide, Histrelin, Leuprolide, Relugolix and Triptorelin in Prostate cancer, run by NRG Oncology, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04513717/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04513717> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:drugs <https://onco.cc/drugs/apalutamide/>, <https://onco.cc/drugs/bicalutamide/>, <https://onco.cc/drugs/buserelin/>, <https://onco.cc/drugs/degarelix/>, <https://onco.cc/drugs/flutamide/>, <https://onco.cc/drugs/goserelin/>, <https://onco.cc/drugs/histrelin/>, <https://onco.cc/drugs/leuprolide/>, <https://onco.cc/drugs/relugolix/>, <https://onco.cc/drugs/triptorelin/> .